CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the Second Quarter of 2024
05 4월 2024 - 1:00AM
Business Wire
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the
world’s most advanced total artificial heart, aiming to provide a
therapeutic alternative for people suffering from advanced
biventricular heart failure (the “Company” or
“CARMAT”), announces today its participation in the
following scientific and investor conferences during the second
quarter of 2024:
Scientific Conferences
- 44th ISHLT Annual Meeting April 10 to 13, 2024 (Prague,
Czech Republic) Scientific Conference of the International Society
of Heart and Lung Transplantation (ISHLT); one of the largest
events dedicated to the treatment of advanced heart and lung
diseases. The CARMAT team will be present on stand 36. For more
information, click here.
- Mechanical Circulatory Support (MCS) Master-Class 2024
June 7 to 8, 2024 (Turin, Italy) International Society for
Mechanical Circulatory Support (ISMCS) event dedicated to training
in implantation techniques for mechanical circulatory support
systems. CARMAT proctors will present the Aeson® heart implantation
procedure during hands-on sessions. For more information, click
here.
- EACTAIC ECHO Course 2024 June 15 to 18, 2024 (Milan,
Italy) The European Association of Cardiothoracic and Vascular
Anesthesia and Intensive Care (EACTAIC) ECHO 2024 course features
innovations to enhance the learning experience and promote skills
development. For more information, click here.
Investor Conferences
- Gilbert Dupont Société Générale MidCap Forum May 16,
2024 (Paris, France) Investor forum organised by Gilbert Dupont
(Société Générale Group), a leading player in the intermediation
and financial operations in the French small and mid-cap
segment.
- Portzamparc BNP Paribas Mid & Small Caps Seminar
June 12, 2024 (Paris, France) Mid & Smallcaps conference
organised by Portzamparc, BNP Paribas investment banking partner
specialising in French small and medium-sized companies.
●●●
About CARMAT
CARMAT is a French MedTech that designs, manufactures and
markets the Aeson® artificial heart. The Company’s ambition is to
make Aeson® the first alternative to a heart transplant, and thus
provide a therapeutic solution to people suffering from end-stage
biventricular heart failure, who are facing a well-known shortfall
in available human grafts. The world’s first physiological
artificial heart that is highly hemocompatible, pulsatile and
self-regulated, Aeson® could save, every year, the lives of
thousands of patients waiting for a heart transplant. The device
offers patients quality of life and mobility thanks to its
ergonomic and portable external power supply system that is
continuously connected to the implanted prosthesis. Aeson® is
commercially available as a bridge to transplant in the European
Union and other countries that recognize CE marking. Aeson® is also
currently being assessed within the framework of an Early
Feasibility Study (EFS) in the United States. Founded in 2008,
CARMAT is based in the Paris region, with its head offices located
in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The
Company can rely on the talent and expertise of a multidisciplinary
team of circa 200 highly specialized people. CARMAT is listed on
the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code:
FR0010907956).
For more information, please go to www.carmatsa.com and follow
us on LinkedIn.
Name: CARMAT ISIN code:
FR0010907956 Ticker: ALCAR
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, nor a solicitation of an
order to buy or subscribe to CARMAT shares in any country. This
press release may contain forward-looking statements by the company
regarding its objectives and prospects. These forward-looking
statements are based on the current estimates and anticipations of
the company's management and are subject to risk factors and
uncertainties such as the company's ability to implement its
strategy, the pace of development of CARMAT's production and sales,
the pace and results of ongoing or planned clinical trials,
technological evolution and competitive environment, regulatory
changes, industrial risks, and all risks associated with the
company's growth management. The company's objectives mentioned in
this press release may not be achieved due to these elements or
other risk factors and uncertainties.
Significant and specific risks of the company are those
described in its universal registration document filed with the
French Financial Markets Authority (Autorité des marchés financiers
- the “AMF”) under number D.23-0323 and in its amendment
filed with the AMF on January 17, 2024 under number D.23-0323-A1.
Readers' attention is particularly drawn to the fact that the
company's current cash runway is limited to mid-May 2024. Readers
and investors are also advised that other risks, unknown or not
considered significant and specific, may or could exist.
Aeson® is an active implantable medical device commercially
available in the European Union and other countries recognizing CE
marking. The Aeson® total artificial heart is intended to replace
the ventricles of the native heart and is indicated as a bridge to
transplant for patients suffering from end-stage biventricular
heart failure (INTERMACS classes 1-4) who cannot benefit from
maximal medical therapy or a left ventricular assist device (LVAD)
and who are likely to undergo a heart transplant within 180 days of
implantation. The decision to implant and the surgical procedure
must be carried out by healthcare professionals trained by the
manufacturer. The documentation (clinician manual, patient manual,
and alarm booklet) should be carefully read to understand the
features of Aeson® and the information necessary for patient
selection and proper use (contraindications, precautions, side
effects). In the United States, Aeson® is currently exclusively
available as part of an Early Feasibility Study approved by the
Food & Drug Administration (FDA).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240404913993/en/
CARMAT Stéphane Piat Chief Executive Officer
Pascale d’Arbonneau Chief Financial Officer Tel.: +33 1
39 45 64 50 contact@carmatsas.com
Alize RP Press Relations
Caroline Carmagnol Tel.: +33 6 64 18 99 59
carmat@alizerp.com
NewCap Financial Communication & Investor
Relations
Dusan Oresansky Jérémy Digel Tel.: +33 1 44 71 94
92 carmat@newcap.eu
Carmat (EU:ALCAR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Carmat (EU:ALCAR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024